摘要
目的探讨卵巢浆液性囊腺癌组织中人附睾蛋白4(HE4)和骨桥蛋白(OPN)的表达及其临床意义。方法采用免疫组织化学染色法检测63例卵巢浆液性囊腺癌、10例卵巢交界性浆液性囊腺瘤及10例卵巢浆液性囊腺瘤组织标本中HE4和OPN的表达,分析HE4、OPN表达与卵巢浆液性囊腺癌临床病理特征的关系及相关性。结果在卵巢浆液性囊腺瘤、卵巢交界性浆液性囊腺瘤和卵巢浆液性囊腺癌组织中,HE4表达阳性率分别为0%、60.00%、93.65%;OPN表达阳性率分别为0%、50.00%、84.13%,二者在3种组织间的阳性表达率比较,差异均有统计学意义(P<0.05);HE4和OPN表达的阳性率在晚期组高于早期组,中、低分化组高于高分化组,有淋巴结转移组高于无淋巴结转移组,各组之间HE4和OPN表达的阳性率比较,差异均有统计学意义(P<0.05)。HE4和OPN在卵巢浆液性囊腺癌中的表达呈正相关。结论 HE4和OPN可能在卵巢浆液性囊腺癌发生、发展过程中起重要作用,可作为卵巢浆液性囊腺癌早期诊断的标志物。
Objective To study the expression and its clinical significance of HE4 and OPN in ovarian serous cystadenocarcinomas.Methods Immunohistochemistry method was used to determine the expression of HE4 and OPN in 63 cases of ovarian serous cystadenocarcinoma,10 cases of ovarian bordline serous cystadenoma,and 10 cases of ovarian serous cystadenoma.The relationship between HE4 and OPN protein expression and clinical pathological characteristics in ovarian serous cystadenocarcinoma were investigated,and the correlation of HE4 and OPN expression was analyzed.Results The positive expression rates of HE4 in ovarian serous cystadenoma,ovarian bordline serous cystadenoma and ovarian serous cystadenocarcinoma were 0,60%,93.65%.The positive expresion rates of OPN were 0,50%,and 84.13%.There was significant difference between HE4 and OPN in three groups(P0.05).The positive expression of HE4 and OPN in Ⅲ-Ⅳstage was markedly higher thanⅠ-Ⅱstage,and its positive expression in low-,middle-grade were significantly higher than the high-grade,and its expression with lymph metastasis group was significantly higher than those without lymph metastasis group(P0.05).HE4 and OPN expression had positive correlation in ovarian serous cystadenocarcinomas.Conclusion HE4 and OPN may play an important role in the progression of ovarian serous cystadenocarcinomas,which can be used as early diagnosis markers of ovarian serous cystadenocarcinoma.
出处
《实用临床医药杂志》
CAS
2013年第9期50-53,共4页
Journal of Clinical Medicine in Practice
关键词
卵巢浆液性囊腺癌
人附睾蛋白4
骨桥蛋白
免疫组织化学
ovarian serous cystadenocarcinomas
human epididymis protein 4
osteopontin
immunohistochemistry